PT  - JOURNAL ARTICLE
AU  - Yusuf Ilhan
AU  - Ali Murat Tatli
AU  - Fatih Teker
AU  - Arif Hakan Onder
AU  - Fatih Kose
AU  - Caglayan Geredeli
AU  - Mustafa Karaagac
AU  - Muhammet Ali Kaplan
AU  - Mevlude Inanc
AU  - Sabin Goktas Aydin
AU  - Aysegul Kargi
AU  - Hacı Arak
AU  - Banu Ozturk
AU  - Ali Ayberk Besen
AU  - Oguzhan Selvi
AU  - Mustafa Korkmaz
AU  - Zeynep Oruc
AU  - Oktay Bozkurt
AU  - Ahmet Bilici
AU  - Selami Bayram
AU  - Shute Ailia Dae
AU  - Mustafa Ozdogan
AU  - Hasan Senol Coskun
AU  - Sema Sezgin Goksu
TI  - Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
AID  - 10.1136/ijgc-2021-003165
DP  - 2022 Jan 27
TA  - International Journal of Gynecologic Cancer
PG  - ijgc-2021-003165
4099  - http://ijgc.bmj.com/content/early/2022/01/26/ijgc-2021-003165.short
4100  - http://ijgc.bmj.com/content/early/2022/01/26/ijgc-2021-003165.full
AB  - Objective Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In this study we aimed to evaluate the efficacy of these two regimens for the treatment of metastatic or recurrent cervical cancer.Methods Patients with metastatic or recurrent cervical cancer treated with cisplatin-paclitaxel and bevacizumab or carboplatin-paclitaxel and bevacizumab were retrospectively evaluated in this study. The clinical and demographic characteristics of patients in each group were evaluated. Median overall survival, progression-free survival, and response rates between the two groups were compared.Results A total of 250 patients were included. Overall, the numbers of patients with recurrent disease and metastatic disease were 159 and 91, respectively. The most common histologic subtype was squamous cell carcinoma (83.2%). The median duration of follow-up was 13.6 (range 0.5–86) months. The median progression-free survival was 10.5 (95% CI 9.0 to 11.8) months in the cisplatin-paclitaxel and bevacizumab group (group 1), and 10.8 (95% CI 8.6 to 13.0) months in the carboplatin-paclitaxel and bevacizumab group (group 2) (HR 1.20; 95% CI 0.88 to 1.63; p=0.25). The median overall survival was 19.1 (95% CI 13.0 to 25.1) months in group 1 and 18.3 (95% CI 15.3 to 21.3) months in group 2 (HR 1.28; 95% CI 0.91 to 1.80; p=0.15).Conclusions There is no survival difference between cisplatin or carboplatin combined with paclitaxel and bevacizumab in metastatic or recurrent cervical cancer.Data are available upon reasonable request. The datasets generated during and/or analyzed during this study are available from the corresponding author on reasonable request.